Compare · DFTX vs MTEX
DFTX vs MTEX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Mannatech Incorporated (MTEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MTEX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 334.6x MTEX ($13.8M).
- DFTX has been more active in the news (8 items in the past 4 weeks vs 1 for MTEX).
- DFTX has more recent analyst coverage (8 ratings vs 0 for MTEX).
- Company
- Definium Therapeutics Inc.
- Mannatech Incorporated
- Price
- -
- -
- Market cap
- $4.60B
- $13.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 1
- Recent ratings
- 8
- 0
MTEX
Mannatech Incorporated
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through network marketing channels and a website. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest MTEX
- SEC Form 8-K filed by Mannatech Incorporated
- Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Mannatech Announces Retirement of J. Stanley Fredrick from the Board and Appointment of Robert Toth as Chairman of the Board
- Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mannatech Incorporated
- Mannatech Reports Financial Results for Second Quarter 2026
- SEC Form 4 filed by Chief Financial Officer Haider Yasir
- SEC Form 3 filed by new insider Haider Yasir
- Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Mannatech Announces Appointment of Yasir Haider as Chief Financial Officer